Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3928 Point Eden Way HAYWARD CA 94545-3719 |
Tel: | N/A |
Website: | https://arcusbio.com |
IR: | See website |
Key People | ||
Terry J. Rosen Chairman of the Board, Chief Executive Officer, Co-Founder | Juan Carlos Jaen President, Co-Founder | Robert C. Goeltz Chief Financial Officer |
Jennifer A. Jarrett Chief Operating Officer | Carolyn Tang General Counsel | Dimitry S.A. Nuyten Chief Medical Officer |
Business Overview |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer. |
Financial Overview |
For the three months ended 31 March 2024, Arcus Biosciences Inc revenues increased from $25M to $145M. Net loss decreased 95% to $4M. Revenues reflect License and development service revenue increase from $17M to $135M, Other collaboration revenue increase of 25% to $10M. Lower net loss reflects Interest and other income, net increase of 44% to $13M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.10 to -$0.05. |